TOP TEN perturbations for 1104_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1104_s_at
Selected probe(set): 220755_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1104_s_at (220755_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)

Relative Expression (log2-ratio):3.164978
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted).

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)

Relative Expression (log2-ratio):2.7112255
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)

Relative Expression (log2-ratio):2.6398191
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).

hepatoblastoma study 1 (epithelial mixed) / normal liver tissue

Relative Expression (log2-ratio):2.6219711
Number of Samples:12 / 5
Experimental hepatoblastoma study 1 (epithelial mixed)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):2.58811
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)

Relative Expression (log2-ratio):-2.4763908
Number of Samples:2 / 5
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted).

hepatoblastoma study 1 (embryonal) / normal liver tissue

Relative Expression (log2-ratio):2.3071432
Number of Samples:7 / 5
Experimental hepatoblastoma study 1 (embryonal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):2.2440214
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):2.2130156
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):2.195631
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Organism: Homo sapiens
Gene: 1104_s_at
Selected probe(set): 202581_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1104_s_at (202581_at) across 6672 perturbations tested by GENEVESTIGATOR:

heat shock study 3 / untreated THP-1 cell sample

Relative Expression (log2-ratio):7.255947
Number of Samples:3 / 3
Experimental heat shock study 3
Cultured THP-1 mononuclear cells were treated with heat shock (43°C) for 1 hour followed by a 4 hour recovery period at 37°C.
Control untreated THP-1 cell sample
Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C.

heat shock study 1 (LPS) / untreated THP-1 cell sample

Relative Expression (log2-ratio):6.0620832
Number of Samples:3 / 3
Experimental heat shock study 1 (LPS)
Cultured THP-1 mononuclear cells were treated with heat shock (43°C; 1h) and lipopolysaccharide (1ug/ml; 4h).
Control untreated THP-1 cell sample
Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C.

tumor supernatant activation study 3 / untreated memory CD4 T-cell sample

Relative Expression (log2-ratio):5.9411507
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control untreated memory CD4 T-cell sample
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

IL-4; GM-CSF study 1 (early) / untreated monocyte sample

Relative Expression (log2-ratio):5.689109
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (early)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

Treg activation study 1 (340min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):5.576563
Number of Samples:2 / 2
Experimental Treg activation study 1 (340min)
Regulatory T-cells were stimulated for 340min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (300min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):5.4976053
Number of Samples:2 / 2
Experimental Treg activation study 1 (300min)
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (320min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):5.3719454
Number of Samples:2 / 2
Experimental Treg activation study 1 (320min)
Regulatory T-cells were stimulated for 320min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (280min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):5.348546
Number of Samples:2 / 2
Experimental Treg activation study 1 (280min)
Regulatory T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (360min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):5.309766
Number of Samples:2 / 2
Experimental Treg activation study 1 (360min)
Regulatory T-cells were stimulated for 360min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (240min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):5.2319765
Number of Samples:2 / 2
Experimental Treg activation study 1 (240min)
Regulatory T-cells were stimulated for 240min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Organism: Homo sapiens
Gene: 1104_s_at
Selected probe(set): 200799_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1104_s_at (200799_at) across 6672 perturbations tested by GENEVESTIGATOR:

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):9.4068775
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):9.250498
Number of Samples:4 / 3
Experimental lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):9.223547
Number of Samples:4 / 3
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):9.197033
Number of Samples:43 / 3
Experimental lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; basaloid carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-9.108524
Number of Samples:3 / 22
Experimental lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted).

MDP study 1 (6h; 10ug/ml; HEK293-NOD2) / MDP study 1 (6h; 10ug/ml; HEK293-con)

Relative Expression (log2-ratio):-8.580411
Number of Samples:3 / 3
Experimental MDP study 1 (6h; 10ug/ml; HEK293-NOD2)
Human embryonic kidney HEK293 cell line stably expressing NOD2 WT after activation with 10 ug/ml muramyl dipeptide (MDP) for 6 hours. HEK293-NOD2 WT cells were prepared by the FLP-IN system. Wildtype NOD2 was inserted to the genomic recombination site by FLP-recombinase enzyme. Stable transfected cells were selected for hygromycin B resistance and consequently cultured in MEM, 10% FCS, 1% penicillin/streptomycin, 50 ug/ml hygromycin B. FLP-IN cells were cultivated without FCS for 7 hours and then were incubated with MDP for activation.
Control MDP study 1 (6h; 10ug/ml; HEK293-con)
Human embryonic kidney HEK293-con cell line after activation with 10 ug/ml muramyl dipeptide (MDP) for 6 hours. The control cell line was prepared by transfection of empty vector.

lung cancer study 1 (PDX; basaloid carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):-8.572643
Number of Samples:3 / 4
Experimental lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).

MDP study 1 (2h; 10ug/ml; HEK293-NOD2 L1007fsinsC) / MDP study 1 (2h; 10ug/ml; HEK293-con)

Relative Expression (log2-ratio):-8.489839
Number of Samples:3 / 3
Experimental MDP study 1 (2h; 10ug/ml; HEK293-NOD2 L1007fsinsC)
Human embryonic kidney HEK293 cell line stably expressing NOD2 L1007fsinsC variant after activation with 10 ug/ml muramyl dipeptide (MDP) for 2 hours. HEK293-NOD2 L1007fsins cells were prepared by the FLP-IN system. The NOD2 L1007fsins variant was inserted to the genomic recombination site by FLP-recombinase enzyme. Stable transfected cells were selected for hygromycin B resistance and consequently cultured in MEM, 10% FCS, 1% penicillin/streptomycin, 50 ug/ml hygromycin B. FLP-IN cells were cultivated without FCS for 7 hours and then were incubated with MDP for activation.
Control MDP study 1 (2h; 10ug/ml; HEK293-con)
Human embryonic kidney HEK293-con cell line after activation with 10 ug/ml muramyl dipeptide (MDP) for 2 hours. The control cell line was prepared by transfection of empty vector.

MDP study 1 (2h; 10ug/ml; HEK293-con) / control HEK293-NOD2 cell sample

Relative Expression (log2-ratio):8.432779
Number of Samples:3 / 3
Experimental MDP study 1 (2h; 10ug/ml; HEK293-con)
Human embryonic kidney HEK293-con cell line after activation with 10 ug/ml muramyl dipeptide (MDP) for 2 hours. The control cell line was prepared by transfection of empty vector.
Control control HEK293-NOD2 cell sample
Human embryonic kidney HEK293 cell line stably expressing NOD2 WT. HEK293-NOD2 WT cells were prepared by the FLP-IN system. Wildtype NOD2 was inserted to the genomic recombination site by FLP-recombinase enzyme. Stable transfected cells were selected for hygromycin B resistance and consequently cultured in MEM, 10% FCS, 1% penicillin/streptomycin, 50 ug/ml hygromycin B. FLP-IN cells were cultivated without FCS for 7 hours and then were harvested for RNA extraction.

MDP study 1 (6h; 10ug/ml; HEK293-NOD2 L1007fsinsC) / MDP study 1 (6h; 10ug/ml; HEK293-con)

Relative Expression (log2-ratio):-8.423527
Number of Samples:3 / 3
Experimental MDP study 1 (6h; 10ug/ml; HEK293-NOD2 L1007fsinsC)
Human embryonic kidney HEK293 cell line stably expressing NOD2 L1007fsinsC variant after activation with 10 ug/ml muramyl dipeptide (MDP) for 6 hours. HEK293-NOD2 L1007fsins cells were prepared by the FLP-IN system. The NOD2 L1007fsins variant was inserted to the genomic recombination site by FLP-recombinase enzyme. Stable transfected cells were selected for hygromycin B resistance and consequently cultured in MEM, 10% FCS, 1% penicillin/streptomycin, 50 ug/ml hygromycin B. FLP-IN cells were cultivated without FCS for 7 hours and then were incubated with MDP for activation.
Control MDP study 1 (6h; 10ug/ml; HEK293-con)
Human embryonic kidney HEK293-con cell line after activation with 10 ug/ml muramyl dipeptide (MDP) for 6 hours. The control cell line was prepared by transfection of empty vector.